Keros Therapeutics Walks the Walk: DMD and ALS Trials in View as Cash Runway Expands to 2028

Keros Therapeutics, Inc. (Nasdaq: KROS) reported its 2025 results in a presentation that leans into execution over euphoric speculation. The company posted a fourth-quarter net loss of $23.5 million and, for the full year, a net income of $87.0 million, mostly driven by revenue tied to its Takeda license agreement. With rinvatercept advancing toward Phase 2 in Duchenne muscular dystrophy (DMD) and regulatory conversations starting for a Phase 2 in amyotrophic lateral sclerosis (ALS), KROS is signaling a shift from funding gambits to real clinical milestones—while preserving a cash runway into the first half of 2028.

For readers chasing the usual earnings metrics, the press release emphasizes net income and losses rather than per-share figures, leaving an EPS figure or EPS consensus to the analysts’ notebooks. Still, the enterprise value story hinges less on a point estimate of EPS and more on revenue visibility, program progress, and the durability of Takeda collaboration economics.

Corporate Highlights

Board and leadership changes: In February 2026, Keros announced the appointment of Charles Newton to its board of directors, effective March 9, 2026. Concurrently, Carl Gordon, Ph.D., C.F.A., will step down as a director.
Executive updates: Esther Cho, J.D., Senior Vice President and General Counsel, was promoted to Chief Legal Officer, effective February 24, 2026.

Selected Anticipated Program Milestones

The company's near-term focus centers on rinvatercept for DMD and ALS. The Company expects to commence a Phase 2 trial in DMD in Q2 2026 and plans to engage regulators on a Phase 2 design for ALS in H2 2026.

2025 Financial Results

Keros reported a net loss of $23.5 million for the fourth quarter and net income of $87.0 million for the year ended December 31, 2025, versus a Q4 net loss of $46.0 million and a full-year net loss of $187.4 million in 2024. The year-over-year improvement in profitability metrics was largely driven by revenue related to the Takeda license agreement, offset by ongoing research and development and investments in clinical and corporate goals.

Research and development expenses were $17.9 million for the fourth quarter and $129.6 million for the year ended December 31, 2025, down from $45.6 million in Q4 and $173.6 million for the year 2024, largely reflecting the transition of elritercept-related R&D costs to Takeda.

General and administrative expenses were $11.7 million for Q4 and $46.8 million for the year, compared with $10.7 million for Q4 and $40.8 million for the year 2024. The annual increase in G&A is described as driven by external expenses and corporate activities, partially offset by lower compensation costs tied to headcount reductions.

Balance Sheet and Cash Runway

As of December 31, 2025, Keros held cash and cash equivalents of $287.4 million, down from $559.9 million at the end of 2024. The decline is attributed to a share repurchase program and a cash tender offer. On current operating assumptions, the company expects this balance to fund operating expenses and capital expenditures into the first half of 2028.

About Keros Therapeutics

Keros is a clinical-stage biopharmaceutical company focused on developing therapeutics addressing disorders tied to dysfunctional signaling of the TGF-β family. The company positions itself as a leader in understanding the TGF-β pathway’s role across tissues such as skeletal muscle, bone, adipose tissue, heart, and blood, aiming to deliver protein therapeutics with potential disease-modifying benefits.

What This Might Portend for KROS and Peers

The 2025 results underscore a pivot from high upfront burn toward milestone-driven progress and disciplined cash management. The Takeda collaboration revenue acts as a stabilizing windfall, but the real driver for future valuation will be the execution of Rinvartercept trials and regulatory alignments. If DMD and ALS Phase 2 programs advance as planned, the revenue outlook attached to these milestones could begin to influence stock-price dynamics even before any near-term commercialization.

In the context of peers, Keros’ strategy—significant R&D investment balanced by meaningful external revenue—offers a template for small- to mid-cap biotech teams facing a similar crossroads: how to preserve optionality in high-uncertainty biology while managing burn and maintaining governance that attracts long-term investors. The presence of a robust cash runway into 2028 provides a cushion for strategic moves, including potential partnerships or licensing discussions as trial readouts approach.

For traders and analysts tracking EPS and earnings surprises, the absence of a disclosed EPS figure in the release means attention will sharpen on quarterly cadence and per-share economics once GAAP or non-GAAP metrics are published in future filings or earnings calls. The EPS consensus, if any, will hinge on whether R&D cadence accelerates or if Takeda-related revenue continues to reliably offset operating costs. In the meantime, the key signal remains: the company has money to shepherd its lead programs through pivotal readouts, not to monetize a near-term product launch yet.

Looking ahead, investors will want to watch how the boardroom and leadership changes shape governance and strategic focus. A fresh director, a newly promoted CLO, and a disciplined capital plan could reduce execution risk, but they also bring questions about how resource allocation aligns with Rinvat… er, Rinvartercept milestones and partner interactions—an area where precision matters just as much as the biology.

In sum, KROS is transitioning from a funding phase to a milestones-driven narrative, anchored by a facially simple but strategically meaningful revenue stream from Takeda and a clear plan to push rinvatercept through Phase 2 milestones. For anyone tracking earnings in the small-cap biotech space, the ticker KROS now carries a heavier emphasis on program execution and capital discipline—metrics that, over time, may translate into a more durable EPS profile and a more navigable revenue forecast path.